On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
REGULATORY
Pricing OK’ed for Dupixent, Tecentriq, Lynparza, and More; Parmodia Skips Listing Yet Again
A key health ministry reimbursement panel on April 11 gave the nod to NHI prices for a batch of new drugs for their listing on April 18, including big names like Dupixent (dupilumab), Tecentriq (atezolizumab), and Lynparza (olaparib). Meanwhile, Parmodia…
To read the full story
Related Article
- Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
- Chuikyo Holds 1st Listing Discussions since Overhaul, US Reference Prices Show Marked Declines after Rule Change
April 12, 2018
- MHLW OKs Dupixent, Tecentriq, Lynparza, and More
January 22, 2018
- In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time
November 20, 2017
- Livalo Successor Parmodia Skips August Listing as Price Negotiation Hits Snag, Celgene’s Istodax Too
August 24, 2017
REGULATORY
- Pfizer to Supply COVID-19 Vaccine Doses for 60 Million People in Japan
August 3, 2020
- PMDA Reviewing Safety Risks for Plaquenil, Relumina
August 3, 2020
- PMDA Provided Preliminary Info on MID-NET Use for Free in “Just Under 10 Cases”: Official
July 31, 2020
- MHLW Finds 57 Suspected Violations in Drug Detailing Activities in FY2019
July 30, 2020
- AMED’s Drug Discovery Library under CiCLE Program Ready to Start Operations
July 30, 2020
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…